CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Boao Lecheng pilot zone
Chiesi Group Launches First EB Wound Treatment in China
The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative...
Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor
Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of...
Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide
Visen Pharmaceuticals (HKG: 2561) announced today that its innovative drug palopegteriparatide (TransCon PTH) has received official...
Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia
Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced that its RYJUSEA (atropine sulfate hydrate) has...
FDA-Approved Smile System Launches in Lecheng for ADHD Treatment
On July 22, 2025, the innovative non-pharmacological ADHD treatment medical device “Smile” (ADHD Transcutaneous Nerve...
Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders
Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...
Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment
Boao Super Hospital in Hainan last week successfully introduced Xiaflex (collagenase clostridium histolyticum), a nonsurgical...
Gilead’s Lenacapavir Approved in Hainan for HIV-1 Pre-Exposure Prophylaxis
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir,...
Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes
Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...
Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...
Hainan Unveils 20 Measures to Boost Pharmaceutical Industry Reform and Quality
The General Office of the People’s Government of Hainan Province has released the “Implementation Plan...
Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone
Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...
La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone
Switzerland-based Clinique La Prairie Holistic Health SA has received approval for its functional nutrient product...
Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...
CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...
Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia
Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...
Hainan Unveils Biomedical New Technology Policy to Boost Medical Innovation
In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission,...
Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management
The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces...
Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy
The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...